COVID-19 Resources

Medicines Use in the treatment of COVID-19

  • As evidence emerges from clinical trials, recommendations regarding the use of some disease-modifying medicines in COVID-19 can now be made, while the use of other disease-modifying medicines remains best limited to a clinical trial setting. Recommendations can also be made where the use of some medicines should not occur. The Australian Living Guidelines for the clinical care of people with COVID-19, updated regularly, is the nationally recognised source for specific, patient-focused recommendations on management and care of people with suspected or confirmed COVID-19. NSW TAG has developed the following supporting documents to assist clinicians and patients/carers if the medicines are used for hospitalised adults with COVID-19.

By downloading any document from this webpage, you agree that you have read, accepted and agreed to the Terms and Conditions (also further down below). If you do not agree with these terms and conditions, do not download.

  • Leaflets and consent forms have an allocated field in the header to insert the name of the hospital/local health district once they have been approved for use.

  • 1. Patient and Family Information Leaflets

  • 2. Consent Forms

    Informed consent (preferably written) should be obtained for the use of medicines to treat COVID-19, especially those that are unregistered or used in an off-label manner. The consent should be documented in the patient’s Health Record, including when verbal informed consent is obtained. The Doctors Declaration section in the above consent forms can be copied and pasted to assist documentation in the electronic medical record if verbal informed consent is obtained. The NSW TAG Checklist for Written Consent: Unregistered/Off-label Use of Medicines may assist and is available here.

    To assist in reducing the risk of cross contamination during the process of obtaining written consent from a patient with COVID-19, Hand Hygiene should be performed before/after contact with the consent form (patient and healthcare worker) and any pens/accessories used should be cleaned. A local process should be implemented to manage the consent form process involving the patient and some possible options include:

    1. Obtaining a digital photo version of the signed consent form and emailing to the appropriate staff member for upload into the patients’ Health Record. (Ensure photo provides clear image of signatures).
    2. Sealing the consent form in a plastic bag and quarantining until potential contamination by SARS-CoV-2 is no longer suspected. The original can then be filed in the patient’s Health Record.
    3. If verbal informed consent obtained, there are various options for inclusion into the electronic medical records application e.g. free text typing by the prescriber or uploading a voice recording of the prescriber advising the patient about the medicine and its potential benefits and harms.

    Further guidance is available in the Consent to Medical and Healthcare Treatment Manual, particularly Section 4.

  • Summary Guidances for Pharmacological Management of Hospitalised Patients with COVID-19

    • Adults (excluding pregnant or breastfeeding women) – Summary Guidance V1.1 (20 September 2021) – [Download PDF]
    • Pregnant or breastfeeding women – Summary Guidance V1.1 (20 September 2021) – [Download PDF]
    • Children or adolescents – Summary Guidance V1 (13 August 2021) – [Download PDF]

     

  • 3. Drug Guidelines

    • Remdesivir – Drug guideline – Version 1.5 (15 March 2021) [Download PDF]
    • Dexamethasone – Drug guideline – Version 1.4 (13 April 2021) [Download PDF]
    • Tocilizumab – Drug guideline – Version 2.1 (15 July 2021) [Download PDF]
    • Baricitinib – Drug guideline – Version 1.1 (6 August 2021) [Download PDF]
    • Sotrovimab – Drug guideline – Version 1.1 (2 Sep 2021) [Download PDF]
  • 4. Prescribing Declaration/IPU Forms and Outcome Reporting Forms

    Prescribing Declaration/IPU and outcome reporting should occur as per local governance processes.

    A NSW TAG drug registry using online reporting processes is now available for NSW Health and affiliated hospitals.

    An instructions guide for QARS is available here for the online process (step by step with screenshots of what to click).


    REMDESIVIR

    NSW Health affiliated hospital DTC representatives have been given access to the online QARS based forms below which are copied and then implemented locally, email sarah.dinh@svha.org.au if you require access.

    10/9/21: See Safety Notice 010/21: Remdesivir 100mg injection –disruption to supply to ensure judicious use

    • Remdesivir – Prescribing Declaration/IPU Form, online QARS based form available locally from your DTC
      • If online form not in use/computer internet access not available, a fillable PDF copy of the form & a corresponding excel template for manual raw data collation are available below

    Access to remdesivir: As at 18/12/20 NSW Health has made stock of remdesivir available at selected hospital pharmacy departments in each LHD. Refer to the factsheet provided by HealthShare: ‘Access to Remdesivir for NSW Health facilities’ for further information. A copy of the completed Remdesivir Prescribing Declaration/IPU Form will be required for stock replacement via iProcurement processes.

    • Remdesivir Outcomes Reporting Form, online QARS based form available locally from your DTC
      • If online reporting form not in use/computer internet access not available, a fillable PDF copy of the form & a corresponding excel template for manual raw data collation are available below

    TOCILIZUMAB

    Alert (current as at 1/9/21): Tocilizumab stocks are at critical level requiring stock preservation (Refer to CEC webpage & Safety Alert 002/21). Baricitinib to be considered instead of tocilizumab unless baricitinib is not clinically suitable. See below for supporting baricitinib resources.

     

    NSW Health affiliated hospital DTC representatives have been given access to the online QARS based forms below which are copied and then implemented locally, email sarah.dinh@svha.org.au if you require access.

    • Tocilizumab – Prescribing Declaration/Streamlined IPU Form, online QARS based form available locally from your DTC
      • If online form not in use/computer internet access not available, a fillable PDF copy of the form & a corresponding excel template for manual raw data collation are available below

    Note:  As at 2/9/21, Tocilizumab Prescribing Declaration Form has been combined with the Streamlined IPU form.

    • Tocilizumab Outcomes Reporting Form,  online QARS based form available locally from your DTC
      • If online reporting form not in use/computer internet access not available, a fillable PDF copy of the form & a corresponding excel template for manual raw data collation are available below

    BARICITINIB

    NSW Health affiliated hospital DTC representatives have been given access to the online QARS based forms below which are copied and then implemented locally, email sarah.dinh@svha.org.au if you require access.

    • Baricitinib – Prescribing Declaration/Streamlined IPU Form, online QARS based form available locally from your DTC
      • If online form not in use/computer internet access not available, a fillable PDF copy of the form & a corresponding excel template for manual raw data collation are available below
    • Baricitinib – Outcomes Reporting Form –  online QARS based form available locally from your DTC
      • If online form not in use/computer internet access not available, a fillable PDF copy of the form & a corresponding excel template for manual raw data collation are available below

    SOTROVIMAB

    NSW Health affiliated hospital DTC representatives have been given access to the online QARS based forms below which are copied and then implemented locally, email sarah.dinh@svha.org.au if you require access.

    • Sotrovimab – Prescribing Declaration/Streamlined IPU online QARS based form available locally from your DTC
      • If online form not in use/computer internet access not available, a fillable PDF copy of the form & a corresponding excel template for manual raw data collation are available below
    • Sotrovimab – Outcomes Reporting Form – coming soon 

     


    SARILUMAB

    Due to current limited stock availability, supporting resources available upon request to NSW TAG

     


    • Template for DTCs – COVID-19 therapeutics IPU Applications and Decisions Log  [Download Excel]

     

  • Key Guidance

    • NSW Health Interim Guidance on use of antiviral and immunomodulation therapy in COVID-19 frequently updated, click here to find the latest version.
    • National COVID-19 Clinical Evidence Taskforce Living Guidelines – link
  • Terms and Conditions of Use

    1. The documents require endorsement by the local Drug and Therapeutics Committee prior to implementation in the hospital/district/network.
    2. The downloaded document will only be used in the care of a hospitalised patient with COVID-19. Its use is not appropriate for a patient in the Hospital in the Home/ Virtual Hospital settings or a community-based patient.
    3. The document user will periodically check for updated documents.
    4. For the reasons stated above, the documents should not be placed on the intranet of a hospital/district/network. A link to this webpage may be provided on the intranet.
    5. The Work on this webpage and the documents downloaded via this webpage are copyright and remain the property of NSW Therapeutic Advisory Group Inc (TAG). No document can be modified without the permission of NSW TAG.

    Any enquiries in regards to copyright, sharing the copyright Works, or requests for further authorisations should be directed in writing to Dr Sasha Bennett at nswtag@stvincents.com.au.

  • Additional Information

    • Terms and Conditions [Download PDF]
    • Acknowledgements
      • Translated documents: NSW TAG acknowledges the NSW Multicultural Health Communication Service, the NSW Ministry of Health and the pharmacists who assisted.
      • Other COVID-19 resources: NSW TAG acknowledges members of the NSW Drug and Therapeutics Advisory Community of Practice – list of members to be published in the future.
    • Visit our COVID-19 homepage
    • Other information
      • In line with National COVID-19 Clinical Evidence Taskforce Living Guidelines:
        • As of 25 May 2020, NSW TAG does NOT ENDORSE OR SUPPORT use of hydroxychloroquine outside a clinical trial. This is due to increasing evidence of harm from observational studies, and the lack of any signal of benefit when using hydroxychloroquine for severe COVID-19 patients in hospital. We have removed hydroxychloroquine documents from this webpage

Page last updated 20 September 2021